Drugs & Therapy Perspectives

, Volume 30, Issue 2, pp 48–54

Natalizumab: a guide to its use in relapsing–remitting multiple sclerosis

Adis Drug Clinical Q&A


The humanized monoclonal antibody natalizumab (Tysabri®) is the first targeted therapy to be approved for the treatment of relapsingremitting multiple sclerosis (RRMS). The annualized relapse rate, the risk of sustained progression of disability and the number of T2-hyperintense and gadolinium-enhancing lesions on magnetic resonance imaging were significantly lower with intravenous natalizumab than with placebo at 2 years in patients with RRMS in a phase III trial. In addition, treatment with natalizumab was generally associated with improved health-related quality of life and was well tolerated. Progressive multifocal leukoencephalopathy (PML) is an uncommon complication of treatment with natalizumab. As long as the risk of PML is managed effectively, natalizumab is a valuable therapeutic option for adults with highly active relapsing forms of MS.


  1. 1.
    Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest. 2012;122(4):1180–8.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.PubMedCrossRefGoogle Scholar
  3. 3.
    McCormack PL. Natalizumab: a review of its use in the management of relapsingremitting multiple sclerosis. Drugs. 2013;73(13):1463–81.PubMedCrossRefGoogle Scholar
  4. 4.
    Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002;58(2):169–78.PubMedCrossRefGoogle Scholar
  5. 5.
    Tysabri (natalizumab) concentrate for solution for infusion: EU summary of product characteristics. London: European Medicines Agency; 2013.Google Scholar
  6. 6.
    Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.PubMedCrossRefGoogle Scholar
  7. 7.
    Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–23.PubMedCrossRefGoogle Scholar
  8. 8.
    Kamat SA, Rajagopalan K, Stephenson JJ, et al. Impact of natalizumab on patient-reported outcomes in a clinical practice setting: a cross-sectional survey. Patient. 2009;2(2):105–12.PubMedCrossRefGoogle Scholar
  9. 9.
    Olofsson S, Wickstrom A, Hager Glenngard A, et al. Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment. Biodrugs. 2011;25(5):299–306.Google Scholar
  10. 10.
    Rudick RA, Miller D, Hass S, et al. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007;62(4):335–46.PubMedCrossRefGoogle Scholar
  11. 11.
    Goodman A, O’Connor P, Polman C, et al. Updated safety and efficacy of natalizumab in the ongoing STRATA study [abstract]. Mult Scler. 2011;17(10 Suppl 1):S444–5.Google Scholar
  12. 12.
    Polman C, Goodman A, Kappos L, et al. Efficacy and safety of natalizumab in the STRATA study [abstract no. P06.173]. In: 62nd annual meeting of the American Academy of Neurology, 10–17 Apr 2010, Toronto (ON).Google Scholar
  13. 13.
    Kappos L, Belachew S, Butzkueven H, et al. Long-term safety and efficacy and association between baseline treatment history and postbaseline relapses in multiple sclerosis patients treatment with natalizumab in the Tysabri® observational program (TOP) [abstract no. P04.134]. Neurology. 2012;78(Suppl).Google Scholar
  14. 14.
    Panzara MA, Bozic C, Sandrock AW. More on melanoma with transdifferentiation. N Engl J Med. 2008;359(1):99 (author reply 100).Google Scholar
  15. 15.
    Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69(14):1391–403.PubMedCrossRefGoogle Scholar
  16. 16.
    Barts and The London School of Medicine and Dentistry. Mulitple sclerosis research: natalizumab PML update: September 2013. 2013. http://multiple-sclerosis-research.blogspot.co.nz/2013/10/natalizumab-pml-update-september-2013.html. Accessed 29 Nov 2013.
  17. 17.
    Plavina T, Subramanyam M, Bloomgren G, et al. Anti-JCV antibody index further defines PML risk in natalizuamb-treated MS patients [poster]. In: 27th annual meeting of the Consortium of Multiple Sclerosis Centers; 29 May to 1 Jun 2013, Orlando (FL).Google Scholar
  18. 18.
    Plavina T, Subramanyam M, Bloomgren G, et al. Use of JV virus antibody index to stratify risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosis [abstract no. O228]. J Neurol. 2013;260(Suppl 1):S13.Google Scholar
  19. 19.
    Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81(10):865–71.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2013

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations